Warning: in_array() expects parameter 2 to be array, null given in /home/pharmalicensing/public_html/detail.php on line 234

Warning: in_array() expects parameter 2 to be array, null given in /home/pharmalicensing/public_html/inc_stats.php on line 82

Warning: array_push() expects parameter 1 to be array, null given in /home/pharmalicensing/public_html/inc_stats.php on line 85
Pharmalicensing | Life Science's Global Technology Marketplace
Save this technology
Save to Existing Project
Save to a New Project
Anti-Cancer Agent(AG60), Anti-Hepatitis, Anti-Fibrotic Agent, Anti-BPH Agent, Anti-Hypertensive & Cholesterol Lowering Agent, Anti-Cataract Agent_Medvill
Korea Health Industry Development Institute (KHIDI) South Korea flag South Korea
Abstract ID:
Anti-Atopic Dermatitis Cosmetics, Anti-Acne Cosmetics, Anti-Oxidants Vitaplus...
Contact Yong U Kim
Email me a copy of this message

Products in Company Pipeline




Anti-cancer agent

(AG60) --- chemicals


•      Patent registration:  Korea and US

•       Pre-clinical studies approval; KFDA(Korean Food and Drug Administration (IND)

- Mode of Action:

•        Inhibition of tumor cell proliferation

•        Suppression of transcription factors (NF-kB and AP-1)

•        Anti-angiogenesis

•        Induction of apoptosis

Anti-hepatitis, anti-fibrotic agent - plant extract


- Patent registered in Korea

- Patents are pending in China and Japan

  China is a big market (60% of population is infected with hepatitis B virus)

- Efficacy:

•       Inhibition of liver fibrosis

•       Anti-viral activities against Hepatitis B virus and Hepatitis C virus (in a several human cases)

- Mode of action:   

 Inhibition of TGF-b expression

Inhibition of collagen synthesis (type-I)

  Anti-viral activity:

Anti-inflammatory activity

  Immuno stimulating activity

Anti-BPH agent

- Patents resistered in Korea and US

- Patents are pending in UK, France and Gernamy

- Efficacy:

    Anti-inflammatory activity: carrageenin paw-edema test

    Analgesic effect: acetic acid writhing test, tail-flick test

    No lowering effect on blood pressure (in 12 weeks treatment in rats)  in therapeutic dose in man

    Effective in benign prostate hyperplasia (BPH), chronic prostatitis, etc.

- Mode of action:

     Inhibition of a-receptor

     Inhibition of smooth muscle contraction: prostate and urethra specific activity (organ specificity )

     No effects on smooth muscles in stomach and bladder (muscarinic organ)     

Anti-hypertensive & cholesterol lowering agent

Patents registered in Korea and US

- Right for Utility model in Germany had been registered

- Efficacy:

    Lowering high blood pressure in SHR (Spontaneous Hypertensive Rat)

    Lowering blood cholesterol

    Lowering blood TG

    Improvement of HDL/LDL Ratio     

   - Mode of action :

     angiotensin converting enzyme inhibitor

     Calcium channel blocker

Anti-cataract agent

- Patent is registered in Korea and US.


   - ex vivo test:  Effects on diabetic cataract (xylose induced cataract) in the organ culture by 50% suppression of the cloudy density.

  -  in vivo test: Inhibition of the cataract formation in diabetic rats. (oral administration for 12 weeks)

Mode of action:

  - Inhibition of aldose reductase (causing the increase in the osmolarity and in the oxicative stress of lens):    IC50 value = 11.3 mg/ml

  - Anti-oxidant activity: chemiluminescent oxidation reaction and better antioxidant effects confirmed as compared with vitamine C



Product in the market






l  Anti-inflammatory and anti-biotic activity in cell & animal model

l  Solutions for symptoms of Acne

l  Inhibition of Propionibacterium acnes

l  Including components for the removal of dead cells in epidermal layer

l  Differentiation of DDS (Day & Night Program) 

l  Natural products in worldwide cosmetics DB

l  Patent filed

l  Safety was confirmed

Anti-atopic dermatitis



l  used non-steroidal plant extract with outstanding efficacy to control the allergy and prevent the skin dry.

l  stabilizing mast cells and prevent the secretion of histamine from mast cells.


Last Updated Jun 2016
Technology Type THERAPEUTIC